(3) Available space for the houseman to consult alone. (4) Living accommodation available on the premises or sufficiently close to hospital accommodation.
A longer attachment is probably essential, and we suggest at least four months. This would also make it feasible to direct some older and more chronically ill patients to the house physician. Such a four-month post would be part of a one-year rotation together with four months each of hospital medicine and surgery. We suggest that the educational aims should be extended to include the hospital medical and surgical parts of the preregistration year and that achievement of these aims should be monitored.
We are very grateful to the house physicians who gave much time in considering our persistent inquiries, to Professor John Bain for his helpful criticism, and to Mrs Jean Gibson for typing the manuscript.
Introduction
Huntington's chorea is a progressive and incurable disease of the central nervous system transmitted through an autosomal gene with complete penetrance.' Each child of an affected person has a 50% chance of inheriting the responsible gene,3 but carriers cannot be identified until there are clinical signs of the disease itself. By the time these appear, a carrier may well have procreated: roughly two-thirds develop symptoms after the age of 29 years.4 A predictive test would break new ground by making it possible to identify carriers before they developed the disease. Non-carriers, who now have to wait until late middle or old age before they can be certain that they have not inherited the gene, could learn of their freedom much earlier.
Almost all of the published attempts5 to develop a definitive test have proceeded on the assumption that the Huntington's chorea gene generates measurable defects long before the clinical features become evident.6 If this hypothesis is true and the gene London NW1 S THOMAS does prove to be "switched on" in utero or at any rate early rather than late in the presymptomatic period of a carrier's life, the deliberations of those professional and lay contributors to the ethical debate who are already taking the eventual development of a test for granted will, in retrospect at least, seem timely. Nor could we regard them as entirely wasted if relevant investigations with a different rationale-analysis of the gene's genetic linkage relations,5 for example-yield all the information that is theoretically obtainable.
At least four features of an ideal test in vivo have been specified in professional publications. Such a test would entail little or no risk to the subject7; it would discriminate between carriers and non-carriers with no false positives or false negatives1; it would produce no ambiguous results'; and its results would be inscrutable to subjects.' Although additional features come readily to the minds of individuals at risk, most fantasised additions (prior indication of a given carrier's age at onset, the subsequent survival period, and the nature and severity of symptoms, for example) appear to be contingent on truly prodiguous advances in our understanding of the disease's aetiology. For To be strictly accurate, calculation of the total posterior probability of someone who has a parent with Huntington's chorea being symptomless at a given age and not having the gene must be based on a knowledge of the ranges of ages at onset of Huntington's chorea in that person's region.3 As age at onset has been regarded as a very vague retrospective point which is notoriously difficult to assess," and there is in any case a shortage3 of regional studies that purport to be comprehensive, those who when counselled simple-mindedly prefer to rely on the prior probability figure of 50O, risk in all symptom-free periods of their lives raise ticklish problems. Given diagnosed patients and their families, have proved formidable obstacles to a comprehensive early-warning system. In South Wales, where a co-ordinated programme of counselling and family support is under way,'2 66',`of an original sample of 92 patients with Huntington's chorea and their spouses were found not to have had "worthwhile" genetic information before completing their families. Of a total of 77 high-risk adults who were counselled early, 52 said that they intended to have fewer children as a result; but the other 25 denied being influenced in this way.
Some offspring of affected parents evidently feel that a deliberate interruption of the line of descent is tantamount to an admission that they themselves will develop the disease. An American woman who had a tubal ligation rather than risk passing on the Huntington's chorea gene felt she was damned if she did and damned if she didn't. "If she tried to accept the fact that she had been sterilised, it meant to her that she had Huntington's disease: if she thought she might remain healthy, she could not bear the thought that she had had herself sterilised for no reason. It was extremely hard for her to act in one circumstance as if she would have Huntington's disease and take appropriate precautions and still maintain the belief that she could as likely be well."9
As much as a decade can pass between the start of prodromal symp- The potential benefits for about half of the counselled offspring of patients with Huntington's chorea are not in dispute: "the person who does not have the gene will be reassured that the disease will not develop and, resulting from this, he will be told that he can have children, safe-in the knowledge that they will also be unaffected."20
The price of the non-carrier's peace of mind would be the carrier's certainty that he or she would develop the disease and might transmit it. For if a tester equivocated about a positive result, and allowed a carrier to procreate in the belief that he or she might not have the gene, there would be justifiable resentment when the symptoms inevitably appeared; and an opportunity to try to reduce the incidence of the disease by early disclosure of the unfortunate facts would be lost. In practice it would be impossible to deceive all carriers by equivocation because many would compare notes with tested non-carrier siblings, and when they learnt that the latter had been given the freedom to have children the realisation that they themselves had the gene would not be far away .20 It has been said that carriers will be "plunged into despondency when they learn that their fate is to be the gradual physical and intellectual decline that the disease inevitably brings ... depression and the risk of suicide would be more or less inevitable."20 This crucial prediction has been challenged by at least one practitioner2l and by a lay contributor to the debate. According to the lay contributor:
"There is understandable reluctance on the part of the medical profession to tell a patient that he or she is destined to acquire an incurable disease. The argument seems to be that, since nothing can be done, such news deprives the patient of hope and thus increases the risk of severe depression and suicide. There are two flaws in this reasoning. The first is that because Huntington's disease is more treatable than ever before, because of the existence of such organisations as the Committee to Combat Huntington's Disease, and because many patients with Huntington's disease live happy, useful lives for many years after the onset of symptoms, there is more reason than ever before for families with Huntington's disease to have hope. Secondly, although extremely early diagnosis serves no medical purpose, it can give a person time to prepare emotionally, financially, and in other ways, so that when the symptoms appear they are not so devastating to the patient and family as they might otherwise be. Giving the patient time to cope, prepare, and plan while still healthy may actually reduce the possibility of suicide."22 Identified and informed carriers might well want to reproduce at a lower rate, overall, than individuals who believe themselves to be at 50%' risk. Analysis of the carefully and conscientiously made declarations of intent in the British study already referred to lends some support to this view. More specific predictions are likely to founder if, as has been suggested, "the human drive for procreation springs from a well so deep that it will always override and take control of human intellect, blending all reason and argument into rationalisation through the process of projection and denial."23
Discussion
Given the absence of a uniform lay concept of Huntington's chorea, the range of personality types likely to be found in a group as large as the "pro-test" population appears to be, and the conflicting forecasts of the psychological implications for tested carriers, a useful starting point for future discussion of the pros and cons of pre cure testing (in the absence of a cure for the disease) might be to acknowledge that we have no way of knowing whether most tested carriers would react constructively or destructively.
For several reasons, the experiences of the 2824 or so documented subjects of an experimental levodopa-based predictive test must not be regarded as directly applicable to other tests. Levodopa itself can cause depression with concomitant suicidal tendencies25 and a positive result, while distressingly producing the phenotypic expression of the disease,7 falls short of proving Huntington's chorea (at this stage, as subjects are presumably told, it merely increases the prediction coefficient26 27). Useful analogies with the experiences of diagnosed victims of progressive disorders other than Huntington's chorea have been suggested,2' but these too leave unclear the impact of a definitive predictive test for Huntington's chorea that is not based on levodopa.
If a reliable test were to be devised before the discovery of a cure, one thing at least seems plain. To turn away every applicant for testing in a well-intentioned and advocated20 endeavour to safeguard the presumed best interests of carriers would be an extremely controversial course, both within the profession28 and outside. For even when the results of the two polls derived from voluntary lay organisations are discounted to some extent, as a sensible precaution against notional sample bias, the high and broadly comparable levels of support for predictive testing in all three polls show that many of those counselled believe that early certainty about the gene would be easier to bear than the present protracted uncertainty.
Until such time, if any, as this belief is shown to be completely groundless, no application for a test should be dismissed out of hand. Each application should be considered on its particular merits. And to reject the applications of couples who have followed medical advice to postpone procreation for five years28 in the fostered expectation that screening will immediately follow the invention of a reliable test should surely be a last resort.
I wish to thank Sir Martin Roth for a most helpful discussion of some aspects of predictive testing. My interest in the subject, which was stimulated by the occurrence of the disease in a relative, is a layman's interest. Unattributed opinions in the article, though rarely wholly original, are personal in the sense that they cannot responsibly be laid at the doors of named individuals or organisations. The Association to Combat Huntington's Chorea, to which I belong, has no official policy.
Readers who wish to make good the deficiencies of so brief a survey will find further references relating to the feasibility and desirability of predictive tests in vivo (and in utero) in M R Hayden's Huntington's
